Zacks Investment Research upgraded shares of Krystal Biotech (NASDAQ:KRYS) from a hold rating to a buy rating in a research note published on Wednesday morning. They currently have $23.00 price objective on the stock.
According to Zacks, “Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States. “
A number of other research firms have also issued reports on KRYS. HC Wainwright boosted their price objective on Krystal Biotech from $32.00 to $35.50 and gave the company a buy rating in a research report on Monday, October 15th. ValuEngine raised Krystal Biotech from a hold rating to a buy rating in a research note on Friday, September 21st. William Blair reaffirmed a buy rating on shares of Krystal Biotech in a research note on Monday, November 5th. Cantor Fitzgerald initiated coverage on Krystal Biotech in a research note on Monday, September 10th. They set an overweight rating and a $28.00 target price on the stock. Finally, Chardan Capital reaffirmed a buy rating and set a $35.00 target price on shares of Krystal Biotech in a research note on Monday, August 6th. Seven equities research analysts have rated the stock with a buy rating, Krystal Biotech presently has a consensus rating of Buy and a consensus target price of $32.60.
Krystal Biotech (NASDAQ:KRYS) last released its quarterly earnings data on Monday, November 5th. The company reported ($0.26) earnings per share (EPS) for the quarter, meeting the Zacks’ consensus estimate of ($0.26). On average, sell-side analysts anticipate that Krystal Biotech will post -0.95 earnings per share for the current fiscal year.
In other Krystal Biotech news, insider Krish S. Krishnan bought 25,000 shares of the business’s stock in a transaction on Thursday, October 18th. The shares were purchased at an average price of $20.00 per share, with a total value of $500,000.00. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 45.80% of the stock is owned by insiders.
A number of institutional investors have recently made changes to their positions in the business. Vanguard Group Inc. raised its stake in Krystal Biotech by 13.1% during the 3rd quarter. Vanguard Group Inc. now owns 173,478 shares of the company’s stock valued at $3,050,000 after acquiring an additional 20,100 shares in the last quarter. Renaissance Technologies LLC bought a new stake in Krystal Biotech during the 3rd quarter valued at $891,000. S Squared Technology LLC bought a new stake in Krystal Biotech during the 3rd quarter valued at $948,000. JPMorgan Chase & Co. raised its stake in Krystal Biotech by 69.0% during the 3rd quarter. JPMorgan Chase & Co. now owns 36,133 shares of the company’s stock valued at $635,000 after acquiring an additional 14,755 shares in the last quarter. Finally, Acadian Asset Management LLC raised its stake in Krystal Biotech by 68.5% during the 3rd quarter. Acadian Asset Management LLC now owns 20,558 shares of the company’s stock valued at $361,000 after acquiring an additional 8,356 shares in the last quarter. 15.38% of the stock is currently owned by hedge funds and other institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Recommended Story: Technical Analysis of Stocks, How Can It Help
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.